ClinicalTrials.gg
Not yet recruitingNCT06852573Updated Feb 28, 2025

Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus

A Phase 1 interventional study of ZM001 Injection in Systemic Lupus Erythematosus, sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. (part of Imunopharm Technology Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is an open, single-arm, phase I clinical study of ZM001 in patients with refractory systemic lupus erythematosus

Read the detailed description

This study is planned to enroll 12-30 patients with refractory SLE in a dose-escalation "3+3" design with 4 dose groups, 2.5×10\^7 CAR-T cells, 5×10\^7 CAR-T cells, 1×10\^8 CAR-T cells and 2×10\^8 CAR-T cells. Each dose group is planned to enroll 3-6 subjects to evaluate its safety. -T cells. 3-6 subjects are planned to be enrolled in each dose group to assess safety, and if subjects in a dose group have a horizontal dose-limiting toxicity (DLT) incidence of≤ 1/6 within 28 days of infusing back, cell infusing back into the next dose group of subjects may be initiated. One or two dose groups will be selected to enroll additional subjects in the study for the extension phase based on the opinion of the Drug Safety Monitoring Board, and 3-6 additional subjects are proposed to be enrolled in each selected dose group for further evaluation of safety and efficacy.

This study will be divided into a screening period, a cell collection period, a chemotherapy pretreatment period, a return infusion and a follow-up period, and within 28 days of return infusion the investigator will assess whether a DLT (Dose limited toxicity) event has occurred to confirm the safety of this dose group.

02

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • ZM001 CD19 CAR-T
  • refractory systemic lupus erythematosus
03

In context

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's planned enrollment of 18 is below the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd. is the lead sponsor of 27 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a diagnosis of systemic lupus erythematosus according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria;
  2. This trial enrolled patients with SLE and required the following prior treatment history for refractory patients:

    1. Adequate standard therapeutic doses of , , and at least one biologic therapy combination regimen for at least 2 months prior to screening are required, and the dose is stable for >2 weeks and the disease remains moderately to severely active.
    2. Immunosuppressants: at least one or more of cyclophosphamide, mycophenolic acids, azathioprine, and calcineurin phosphatase inhibitors have been used;
    3. Biologics: at least one or more of belimumab, tetracycline, rituximab;
    4. Oral glucocorticoids must meet the following requirements:
    5. Prednisone (or equivalent) ≥ 7.5 mg/day and ≤ 60 mg/day;
    6. There is no minimum daily dose requirement for glucocorticoids when used in combination with immunosuppressive and/or biological agents.
  3. Compliance at screening: positive anti-nuclear antibodies (ANAs) or positive anti-dsDNA antibodies or positive anti-Smith antibodies;
  4. SLEDAI-2000 score ≥7 at screening or combination of vital organs, such as severe immune thrombocytopenia ( \<30*×10\^9/L or \<50*×10\^9/L with bleeding tendency);
  5. Age 18-70 (including boundary values), male and female;
  6. Survival is expected to be more than 3 months;
  7. Women of who had a negative blood pregnancy test prior to the start of the trial and who agreed to use effective for the duration of the trial up to the last follow-up visit; male subjects whose partners were of childbearing potential agreed to use effective contraception for the duration of the trial up to the last follow-up visit;
  8. Blood cell analysis within 3 days prior to single collection:

    1. (Hb) ≥ 80 g/L;
    2. Neutrophils ( (ANC)) ≥ 1.5 x 109/L;
    3. Platelet count (PLT) ≥ 20 x 109/L;
    4. Absolute lymphocyte count ≥ 0.6 x 109/L and percentage of lymphocytes ≥ 10%;
  9. Liver, kidney, heart, lung function, and coagulation meet the following requirements:

    1. ≥ 40 ml/min or serum creatinine ≤ 1.5 x (ULN);
    2. , AST ≤ 2.5 x ULN and total ≤ 1.5 x ULN (for subjects with Gilbert's syndrome, ALT, AST ≤ 5 x ULN and total bilirubin ≤ 3 x ULN);
    3. International ratio () and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;
    4. ≥ 50%;
    5. Finger pulse oximetry saturation >92% in non-oxygenated state;
  10. Vascular access is adequate for cell collection, and lines are available for patients with existing central venous catheters;
  11. The person himself/herself or his/her legal guardian agrees to participate in this trial and signs the form.

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing or CNS disorders not due to lupus at the time of screening, such as convulsive seizures, epilepsy, epileptic seizures, cerebrovascular disease (ischemia/hemorrhage), cerebral edema, reversible posterior leukoencephalopathy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disorders, organic brain syndromes, encephalitis, CNS vasculitis, or psychiatric disorders; epilepsy due to lupus, stable without seizures for a period of 1 year prior to the screening period Stable seizure-free for 1 year may also be screened.
  2. Treatment with hemodialysis, or high-dose (prednisone ≥1.5 mg/kg/d or equivalent glucocorticoid therapy for ≥14 days) was required within 2 months prior to screening.
  3. Presence of still uncontrolled lupus crisis within 2 months prior to screening that is assessed by the investigator to be unsuitable for participation in this study;
  4. Massive plasmapheresis (e.g., pleural effusion, abdominal effusion) with symptoms of compression that cannot be controlled with treatment;
  5. Active disease other than SLE (e.g., Crohn's disease, rheumatoid arthritis) requiring systemic therapy within 2 years prior to the start of screening;
  6. Patients who have previously received or are awaiting hematopoietic stem cell/bone marrow transplantation or organ transplantation;
  7. Those who have received prior genetically modified cell therapy, such as TCR-T therapy, CAR-T therapy, etc;
  8. Use of any other clinical drug for the treatment of SLE within 4 weeks prior to screening. However, treatment ineffectiveness or disease progression that has passed at least 3 half-lives prior to screening will allow enrollment;
  9. History of grade ≥2 bleeding within 30 days prior to screening or need for long-term continuous treatment with anticoagulants (e.g., warfarin, low molecular heparin, or factor Xa inhibitors);
  10. Plasma exchange, plasma separation, hemodialysis, intravenous immunoglobulin (IVIG) within 14 days prior to cell collection;
  11. Those who used drugs to stimulate bone marrow hematopoietic cell production within 5 days prior to cell collection;
  12. Live or within 6 weeks prior to screening;
  13. Active or virus, defined as subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and whose peripheral blood HBV-DNA test is above the lower limit of detection (HBsAg-positive but with a peripheral blood HBV-DNA test below the lower limit of detection according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B, 2022 Edition, at least 4 weeks of antiviral therapy prior to the first administration of the investigational drug, and continued antiviral therapy for 6 to 6 months during the study, with monitoring of HBV DNA and levels required may be every 1\~month. Antiviral therapy for at least 4 weeks prior to the first dose of study drug and continued for 6-12 months during the course of the study, with monitoring of HBV DNA, HBsAg, and ALT levels at 1-3 month intervals); Hepatitis C Virus (HCV) antibody-positive subjects with a peripheral blood HCV-RNA test higher than the lower limit of detection; antibody-positive subjects; and syphilis antibody-positive subjects;
  14. Active EBV and cytomegalovirus, defined as subjects with IgM antibody-positive or IgM antibody-negative EBV serum but higher-than-normal EBV-DNA; and cytomegalovirus (CMV) serum IgM antibody-positive or IgM antibody-negative cytomegalovirus but higher-than-normal CMV-DNA;
  15. Presence of (COPD), interstitial lung disease (ILD), and clinically significant pulmonary function test abnormalities;
  16. Medically uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg) or a history of any of the following cardiovascular diseases within 6 months prior to the start of screening: long syndrome or QTc interval >480 ms; complete left bundle branch block, second/third degree atrioventricular block; severe uncontrolled cardiac arrhythmias that require medication; history of chronic congestive heart failure with class ≥3 (refer to Appendix 2) cardiac less than 50% within 6 months prior to screening; ≥3; CTCAE ≥3; and CTCAE ≥3. controlled arrhythmia; history of chronic congestive heart failure with NYHA class ≥3 (refer to Attachment 2) cardiac ejection fraction less than 50% within 6 months prior to screening; CTCAE class ≥3 cardiac valvular disease; myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, history of severe pericardial disease, or other clinically significant cardiac disease within 6 months prior to screening;
  17. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to initiation of screening;
  18. Other untreated malignant tumors within the previous 5 years or concurrently, except cervical cancer in situ, basal cell carcinoma of the skin, and ductal carcinoma in situ of the breast;
  19. Infections (fungal, bacterial, viral, or other) that require intravenous antimicrobial control or are uncontrollable, for simple urinary tract infections, and for bacterial pharyngitis, may be enrolled if the investigator evaluates that they can be controlled by curative treatment;
  20. The presence of any factors affecting compliance with the protocol, or the unwillingness or inability of the subject to comply with the procedures required in the study protocol, as judged by the investigator.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    ZM001 Injection

    After preconditioning with chemotherapy, ZM001 Injection will be evaluated

    Biological: ZM001 Injection

Interventions

  • BiologicalZM001 Injection

    ZM001 injection, 2.5× 10\^7 CAR-T cells, 5× 10\^7 CAR-T cells, 1× 10\^8 CAR-T cells and 2× 10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Related adverse events (AEs)

    Incidence of adverse events associated with ZM001 reinfusion within 28 days of ZM001 reinfusion, type, frequency, and severity of abnormal clinically significant vital signs, electrocardiograms, and laboratory tests examined, including dose-limiting toxicity

    Time frame: Up to 28 days after CAR-T cell infusion

Secondary outcomes

  1. Lupus Low Disease Activity State (LLDAS)

    Proportion of subjects achieving Lupus Low Disease Activity State (LLDAS) at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  2. disease remission (DORIS)

    Proportion of subjects achieving disease remission (DORIS) at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  3. SLEDAI-2K score

    SLEDAI-2K score change from baseline values at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  4. British Isles Lupus Assessment Group Index (BILAG-2004)

    British Isles Lupus Assessment Group Index (BILAG-2004) change from baseline values at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  5. Clinician's general judgment (PGA)

    Clinician's general judgment (PGA) change from baseline values at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  6. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS)

    Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) change from baseline values at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  7. SLE Response Index 4 (SRI-4)

    Proportion of subjects achieving SLE Response Index 4 (SRI-4) at 12 weeks/24 weeks after ZM001 infusion

    Time frame: Up to 24 week after CAR-T cell infusion

  8. quality of life (SF-36)

    quality of life (SF-36) change from baseline values at 12, 24, 48, and 72 weeks after ZM001 infusion back

    Time frame: Up to 72 week after CAR-T cell infusion

  9. immunoglobulin-IgG

    Changes of immunoglobulin-IgG after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  10. immunoglobulin-IgM

    Changes of immunoglobulin-IgM after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  11. immunoglobulin-IgA

    Changes of immunoglobulin-IgA after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  12. immunoglobulin-IgE

    Changes of immunoglobulin-IgE after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  13. anti-ds-DNA antibody

    Changes of anti-ds-DNA antibody after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  14. anti-nuclear antibody

    Changes of anti-nuclear antibody after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  15. complement C3

    Changes of complement C3 after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  16. complement C4

    Changes of complement C4 after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  17. Time to peak (Tmax)

    Time to peak (Tmax) in patients' peripheral blood after ZM001 infusion

    Time frame: Up to 28 days after CAR-T cell infusion

  18. peak expansion (Cmax)

    peak expansion (Cmax) in patients' peripheral blood after ZM001 infusion

    Time frame: Up to 28 days after CAR-T cell infusion

  19. area under the curve (AUC)

    area under the curve (AUC) in patients' peripheral blood after ZM001 infusion

    Time frame: Up to 28 days after CAR-T cell infusion

  20. survival time of CAR-T cells

    survival time of CAR-T cells in patients' peripheral blood after ZM001 infusion

    Time frame: Up to 28 days after CAR-T cell infusion

  21. CD19+ B cell levels

    Correlation of CD19+ B cell levels in peripheral blood with reduced disease activity after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

  22. major B cell functional subpopulations

    changes in major B cell functional subpopulations (initial B cells, memory B cells, and category-switching B cells) in peripheral blood with reduced disease activity after ZM001 infusion

    Time frame: Up to 96 week after CAR-T cell infusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Feb 2026, 12 months later.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 12 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 28, 2025
StartEst.
Feb 20, 2025
Primary completionEst.
Feb 20, 2026
CompletionEst.
Aug 20, 2027
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06852573
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Feb 20, 2025 (estimated)
Primary completion
Feb 20, 2026 (estimated)
Completion
Aug 20, 2027 (estimated)
Last update
Feb 28, 2025

Study contacts

Fei Wu
Contact
wufei@imunopharm.com
8615801390058
Mengtao Li, PhD
Contact
Mengtao.li@cstar.org.cn
861065296114

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion